Expression and Release of CD27 in Human B-Cell Malignancies

• Published in: Blood 1993-12, Vol.82 (11), p.3430-3436
• Main Authors: van Oers, M.H.J., Pals, S.T., Evers, L.M., Schoot, C.E. van der, Koopman, G., Bonfrer, J.M.G., Hintzen, R.Q., Borne, A.E.G. Kr. von dem, Lier, R.A.W. van
• Format: Article
• Language: English
• Subjects: B-Lymphocytes - immunology; Biological and medical sciences; Burkitt Lymphoma - immunology; Hematologic and hematopoietic diseases; Hematopoietic Stem Cells - immunology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - immunology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Non-Hodgkin - immunology; Medical sciences; Tumor Necrosis Factor Receptor Superfamily, Member 7 - analysis
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V82.11.3430.3430

CD27, a transmembrane disulfide-linked 55-kD homodimer, belongs to the nerve growth factor-receptor family, a group of homologous molecules involved in lymphocyte differentiation and selection. It is expressed on mature thymocytes, peripheral blood T cells, and a subpopulation of B cells. We investigated the expression of CD27 on malignant B cells representative for a broad range of stages in physiologic antigen-independent and -dependent B-cell development. In normal lymphoid tissue CD27+ B cells were only found in the peripheral blood (29.8% ± 10.8%, n = 13) and in germinal centers. With the exception of pro-B and the majority of pre-pre-B acute lymphocytic leukemias and of myelomas, CD27 expression of variable intensity was detected on almost all immature and mature malignant B cells tested. Moreover, using a sandwich enzyme-linked immunosorbent assay we could show the presence of sometimes very high (up to 6,000 U/mL; normal values 1